PDCD1 and head and neck squamous cell carcinoma: CheckMate 141, the first reported randomized phase III trial of a PD-1 inhibitor in HNSCC, CheckMate 141, the first reported randomized phase III trial of a PD-1 inhibitor in HNSCC, focused on enrolling patients who had experienced disease progession within six months of undergoing platinum-based chemotherapy.